灵北公司是一家专注于精神及神经系统领域的全球性制药公司。灵北拥有超过70年在神经科学领域的前沿的专业研究经验。我们的关注疾病领域为抑郁症、精神分裂症、阿尔茨海默病及帕金森病。<\/p> \n

我们在全球范围内拥有员工5000余人，业务遍及全球55个国家，拥有从研究、开发、生产、到市场推广完整的医药价值链。我们的新产品有很多已进入后期开发，产品遍及全球100多个国家。<\/p> \n

90年代末期，灵北通过与合作伙伴合作的方式进入中国市场。灵北的目标和愿景是以不断改善患者的生命质量为己任，为成为中国精神及神经疾病领域的领导者而不懈努力。<\/p> \n

作为一家专注于精神和神经系统疾病领域的跨国制药企业，在中国处方治疗抑郁症的药物中，灵北公司占据了约23%的市场份额。灵北已上市的药物黛力新^{®<\/sup>、喜普妙^{®<\/sup>、来士普^{®<\/sup>等很好地服务了中国众多抑郁症患者。在治疗阿尔茨海默病方面，灵北推出的易倍申^{®<\/sup>市场份额达到了24%，帮助了成千上万的中国患者及看护。<\/p> \n}}}}

灵北创造的价值来自于我们发现、培育和传播的创新治疗方案。灵北是丹麦在研发方面投入最大的公司之一。通过将治疗帕金森病药物安齐来^{®<\/sup>和治疗抑郁症药物心达悦^{®<\/sup>带入中国，灵北将给更多中国神经精神疾病患者带来新曙光。<\/p> \n}}

灵北致力于精神和神经系统领域的知识普及和教育。2008年灵北学院正式进入中国以来，从最初覆盖北京、上海、广州等大城市十几家医院，到全国几十个大中城市的两百多家医院，发起了一系列关键医学教育活动：痴呆&认知研讨班，WPA -- 灵北学院中国抑郁教育项目，骨干青年医师培训项目。我们的目标是使灵北成为改善中国CNS患者生命质量的领导声音。<\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

参考文献<\/span><\/p> <\/td> \n <\/tr> \n

^{[1]<\/sup> World Health Organization. Depression and other common mental disorders: global health estimates. WHO\/MSD\/MER\/2017.2: 21<\/span><\/p> <\/td> \n <\/tr> \n}

http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf<\/a> <\/span><\/p> <\/td> \n <\/tr> \n

^{[2]<\/sup> World Health Organization. Depression and other common mental disorders: global health estimates. WHO\/MSD\/MER\/2017.2: 21<\/span><\/p> <\/td> \n <\/tr> \n}

http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf<\/a> <\/span><\/p> <\/td> \n <\/tr> \n

^{[3]<\/sup> From the survey report “Impact of Depression at Work” launched in 2014<\/span><\/p> <\/td> \n <\/tr> \n}

^{[4] <\/sup>https:\/\/rd.springer.com\/article\/10.1007\/S00127-006-0151-2<\/a> <\/span><\/p> <\/td> \n <\/tr> \n}

^{[5]<\/sup> Lee S, Tsang A, et al. The epidemiology of depression in metropolitan China. Psychol Med 2009;39(5):735-747) (22.7% sought treatment) <\/span><\/p> <\/td> \n <\/tr> \n}

^{[6]<\/sup> http:\/\/www.who.int\/mediacentre\/news\/releases\/2016\/depression-anxiety-treatment\/en\/<\/a> <\/span><\/p> <\/td> \n <\/tr> \n}

^{[7]<\/sup> The 2015-2020 National Mental Health Workplan of the People's Republic of China<\/span><\/p> <\/td> \n <\/tr> \n}

^{[8]<\/sup> Hou Z et al. Neruosci Bull. 2016 Aug; 32(4): 389-397<\/span><\/p> <\/td> \n <\/tr> \n}

^{[9]<\/sup> Rush AJ et al. Am J Psychiatry 2006; 163(11):1905–1917<\/span><\/p> <\/td> \n <\/tr> \n}

^{[10]<\/sup> Mclntyre&O” Donovan. CanJ Psychiatry 2004; 49(3)<\/span><\/p> <\/td> \n <\/tr> \n}

^{[11]<\/sup> Zimmerman et al. J Clin Psychiatry 2017;73(6):790-795<\/span><\/p> <\/td> \n <\/tr> \n}

^{[12]<\/sup> Zimmerman M, et al. Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res. 2008 Aug;42(10):797-801. <\/span><\/p> <\/td> \n <\/tr> \n}

^{[13]<\/sup> Zimmerman M., et al. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J Clin Psychiatry. 2012 Jun;73(6):790-5.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}
图片 - https:\/\/photos.prnasia.com\/prnh\/20180424\/2111889-1-a<\/a>
图片 - https:\/\/photos.prnasia.com\/prnh\/20180424\/2111889-1-b<\/a>
图片 - https:\/\/photos.prnasia.com\/prnh\/20180424\/2111889-1-c<\/a> <\/p>"]; $("#dvExtra").html(content_array[0]);})();